Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

RNA Sequencing Reveals Mechanisms Underlying Modulation of Hodgkin Lymphoma Cells and Tumor Microenvironment By the PI3K δ/γ Inhibitor, RP6530

Silvia Laura Locatelli, PhD, Francesca Maria Consonni, PhD, Giuseppa Careddu, Simone Serio, Srikant Viswanadha, PhD, Swaroop Kumar VS Vakkalanka, PhD, Lucia Morello, MD, Massimo Magagnoli, MD, Luca Castagna, MD, Armando Santoro, MD, Antonio Sica, PhD, Carmelo Carlo-Stella, MD

Blood (2017) 130 (Supplement 1): 2476.

https://doi.org/10.1182/blood.V130.Suppl_1.2476.2476

Published: 2017

Journal Articles

The Novel Calcium Release-Activated Calcium (CRAC) Channel Inhibitor RP4010 Exerts Potent Antitumor Effects in NOD/SCID/IL2Rg -/- Mice with Diffuse Large B Cell Lymphoma (DLBCL) Cell Line Xenografts

Silvia Laura Locatelli, PhD, Giuseppa Careddu, Massimo Magagnoli, MD, Martina di Trani, Lucia Morello, MD, Srikant Viswanadha, PhD, Swaroop Kumar VS Vakkalanka, PhD, Luca Castagna, MD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2017) 130 (Supplement 1): 4101.

https://doi.org/10.1182/blood.V130.Suppl_1.4101.4101

Published: 2017

Journal Articles

A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma

Yasuhiro Oki, MD, Auris Huen, MD, Prajak J Barde, MD, Kumar Penmetsa, PhD, Alda Ashu, Little Pullokaran, Carol Wilson, Srikant Viswanadha, PhD, Madeleine Duvic, MD

Blood (2016) 128 (22): 3004.

https://doi.org/10.1182/blood.V128.22.3004.3004

Published: 2016

Journal Articles

Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K δ/γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects

Silvia Laura Locatelli, PhD, Francesca Maria Consonni, Giuseppa Careddu, Simone Serio, Srikant Viswanadha, PhD, Swaroop Vakkalanka, PhD, Luca Castagna, MD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2016) 128 (22): 45.

https://doi.org/10.1182/blood.V128.22.45.45

Published: 2016

Journal Articles

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Uday Kumar, Srikant Viswanadha, PhD, Silvia Laura Locatelli, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Lucia Morello, Massimo Magagnoli, Armando Santoro, Andrés J.M. Ferreri, MD

Blood (2016) 128 (22): 3011.

https://doi.org/10.1182/blood.V128.22.3011.3011

Published: 2016

Journal Articles

Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis

Silvia Laura Locatelli, PhD, Giuseppa Careddu, Armando Chierchia, Srikant Viswanadha, PhD, Swaroop Vakkalanka, PhD, Luca Castagna, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2015) 126 (23): 1561.

https://doi.org/10.1182/blood.V126.23.1561.1561

Published: 2015

Journal Articles

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Thamila Saheb, Uday Kumar, Srikant Viswanadha, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Armando Santoro, MD, Silvia Laura Locatelli, PhD, Swaroop Vakkalanka, PhD, Paolo Ghia, MD PhD, Andres J.M. Ferreri

Blood (2015) 126 (23): 1495.

https://doi.org/10.1182/blood.V126.23.1495.1495

Published: 2015

Journal Articles

Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma

Matthew A. Lunning, DO, Julie M. Vose, MD MBA, Marshall T. Schreeder, MD, Nathan Fowler, MD, Loretta J. Nastoupil, MD, Tanya Siddiqi, MD, Susan Blumel, RN, BSN, Emily K. Pauli, BMBS, PharmD, Kathy Cutter, RN, BSN, Warner Tse, RN, Hari P. Miskin, MS, Peter Sportelli, Michael S. Weiss, Swaroop Vakkalanka, PhD, Srikant Viswanadha, PhD, Susan O'Brien, MD

Blood (2014) 124 (21): 801.

https://doi.org/10.1182/blood.V124.21.801.801

Published: 2014

Journal Articles

The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Silvia L Locatelli, PhD, Silvia Tartari, PhD, Luca Castagna, MD, Rita Mazza, Srikant Viswanadha, PhD, Peter Sportelli, Swaroop Vakkalanka, PhD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2014) 124 (21): 4486.

https://doi.org/10.1182/blood.V124.21.4486.4486

Published: 2014

Journal Articles

A Phase I Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic Malignancies

Lydia Scarfò, Prajak J Barde, MBBS, MD, Claudia Fazi, PhD, Uday Kumar, Srikant Viswanadha, PhD, Swaroop Vakkalanka, PhD, Paolo Ghia, MD, Andres J.M. Ferreri, MD PhD

Blood (2014) 124 (21): 3043.

https://doi.org/10.1182/blood.V124.21.3043.3043

Published: 2014

Journal Articles

Addition of RP6530, a Dual PI3Kδ/γ Inhibitor, Overcomes Ibrutinib Resistance in DLBCL Cells in Vitro

Swaroop Vakkalanka, PhD, Seeta Nyayapathy, M.S., Srikant Viswanadha, PhD

Blood (2014) 124 (21): 4497.

https://doi.org/10.1182/blood.V124.21.4497.4497

Published: 2014

Journal Articles

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

Changchun Deng, MD PhD, Mark Lipstein, B.S., Xavier Jirau Serrano, Michael Mangone, PhD, Luigi Scotto, PhD, Owen A O'Connor, MD, PhD, Peter Sportelli, Hari P. Miskin, MS, Srikant Viswanadha, PhD

Blood (2014) 124 (21): 1770.

https://doi.org/10.1182/blood.V124.21.1770.1770

Published: 2014

NARROW

RNA Sequencing Reveals Mechanisms Underlying Modulation of Hodgkin Lymphoma Cells and Tumor Microenvironment By the PI3K δ/γ Inhibitor, RP6530

The Novel Calcium Release-Activated Calcium (CRAC) Channel Inhibitor RP4010 Exerts Potent Antitumor Effects in NOD/SCID/IL2Rg -/- Mice with Diffuse Large B Cell Lymphoma (DLBCL) Cell Line Xenografts

A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma

Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K δ/γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma

The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

A Phase I Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic Malignancies

Addition of RP6530, a Dual PI3Kδ/γ Inhibitor, Overcomes Ibrutinib Resistance in DLBCL Cells in Vitro

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only